Mood disorder

• However, when focusing strictly on the benefits of faith in a divine being—or, in the case of spiritualists, something greater than ourselves—studies have uncovered a number of advantages.
• Faith alone will not bring you happiness or success; you always need to take steps aligned with your goals or vision.
• Here's what their investigation revealed:
  90% believe that they deserve love, respect, and happiness (compared to 77% of Non-believers).
• This type of defense mechanism, known as "Reaction Formation," is a method of redirecting a negative impulse into something positive.

• ADHD is diagnosed using criteria from a document called DSM-5, which include symptoms of inattention, hyperactivity and impulsivity.
• But it is becoming increasingly clear to researchers that the condition also comes with self-control problems, affecting the ability to regulate emotions.
• For example, 2.1% of children with a diagnosis of ADHD also have a mood disorder, such as depression, while 27.4% have an anxiety disorder.
• Children with anxiety and depression symptoms only exhibited those deficits if they also had problems with attention.
• So it seems that one possible route to helping children with ADHD or mood disorders with cognitive development is to focus on improving their attention.

Treatments

• Methylphenidate roughly works by increasing three chemicals in the brain: dopamine, serotonin and noradrenaline.
• Dopamine can improve attention, learning, working memory and motivation, while noradrenaline reduces impulsivity and boosts attention.
• This research suggests that cognitive control, which is associated with frontal areas, can be improved by methylphenidate.
• This should be offered to children with ADHD, in conjunction with pharmacological treatments.

ADHD on the rise

• The number of ADHD diagnoses are rising across the world, and so are prescriptions of methylphenidate.
• In the UK, a study estimated that the use of ADHD medications has increased by almost 800% from 2000 to 2015.
• It may be that the prevalence of ADHD will increase even more in the future as coping strategies become less effective and people seek help and ultimately receive a diagnosis.
• The more we learn about brain basis of ADHD, the easier it will get to treat.

• Gate Neurosciences, a clinical-stage biotechnology company using precision medicine approaches to develop next-generation neuroscience therapies, today announced it has increased its R&D capabilities with new expanded research operations and lab facilities in Evanston, Illinois.
• There, Gate will further build the translational biomarker data package supporting its NMDA receptor modulator portfolio and advance foundational mechanism insights behind its synaptic function-enhancing molecules.
• The expanded research supports parallel clinical development of the “stinel” class including lead oral program zelquistinel in Phase 2 for major depressive disorder (MDD).
• Gate Neuro has expanded its R&D operations with new lab facilities located in Evanston, IL including nearly 2,000 sq.

• The "Neuromodulation Devices Global Market- Forecast To 2029" report has been added to ResearchAndMarkets.com's offering.
• The neuromodulation devices global market is expected to reach $9,427.7 million by 2029 growing at a high single digit CAGR from 2022 to 2029.
• The emergence of neuromodulation as add-on therapy, technological innovations in neuromodulation, expansion in emerging markets and the rise in the number of clinical studies performed provides immense opportunities to the neuromodulation market.
• Based on the product, the neuromodulation global market is segmented into invasive neuromodulation devices and non-invasive neuromodulation devices.